The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Safety will be assessed by incidence of AEs and change from baseline in the following additional safety parameters: clinical laboratory assessments, physical examination, vital signs, and 12 lead electrocardiograms (ECGs)

Secondary Outcome Measures:

Efficacy Measures [ Time Frame: 3 months ]

Efficacy will be assessed by evaluation of change in PSA level, changes from baseline in CT/MRI and bone scans, response rate RECIST criteria and additional special laboratories

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Signed informed consent form

Confirmed cancer of the prostate

Progressing disease in spite of androgen ablation therapy

Able to swallow multiple capsules

Exclusion Criteria:

Participation in another clinical trial < 4 weeks prior to enrollment

Metastatic disease with one or more of the following:

Liver involvement

Bone pain associated with confirmed evidence of metastases

Non-hepatic visceral involvement

The following medications:

Prior treatment with MDV3100, abiraterone, Provenge or TAK700

Prior treatment with ketoconazole

Prior treatment with chemotherapy

Prior radiation therapy completed ≤ 4 weeks prior to enrollment

The following medical conditions:

Active angina pectoris

History of Hepatitis B or Hepatitis C

Known HIV infection

Ongoing hypertension

Note: There are additional inclusion and exclusion criteria. The clinical site center will determine if you are eligible. If you are not eligible for the trial, site staff will detail the reasons to you.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00959959